These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32668248)

  • 1. A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
    Johansson P; Krona C; Kundu S; Doroszko M; Baskaran S; Schmidt L; Vinel C; Almstedt E; Elgendy R; Elfineh L; Gallant C; Lundsten S; Ferrer Gago FJ; Hakkarainen A; Sipilä P; Häggblad M; Martens U; Lundgren B; Frigault MM; Lane DP; Swartling FJ; Uhrbom L; Nestor M; Marino S; Nelander S
    Cell Rep; 2020 Jul; 32(2):107897. PubMed ID: 32668248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
    Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
    Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
    Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
    PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine.
    Gozdz A
    Curr Oncol; 2023 Nov; 30(11):9676-9688. PubMed ID: 37999122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration.
    Clark PA; Bhattacharya S; Elmayan A; Darjatmoko SR; Thuro BA; Yan MB; van Ginkel PR; Polans AS; Kuo JS
    J Neurosurg; 2017 May; 126(5):1448-1460. PubMed ID: 27419830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new method of identifying glioblastoma subtypes and creation of corresponding animal models.
    Zhou X; Li G; An S; Li WX; Yang H; Guo Y; Dai Z; Dai S; Zheng J; Huang J; Iavarone A; Zhao X
    Oncogene; 2018 Aug; 37(35):4781-4791. PubMed ID: 29769617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational validation of personalized treatment strategy based on genetic characteristics of glioblastoma.
    Oh YT; Cho HJ; Kim J; Lee JH; Rho K; Seo YJ; Choi YS; Jung HJ; Song HS; Kong DS; Seol HJ; Lee JI; Yoon Y; Kim S; Nam DH; Joo KM
    PLoS One; 2014; 9(8):e103327. PubMed ID: 25084005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
    Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
    Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.
    Venkatesan S; Lamfers ML; Dirven CM; Leenstra S
    CNS Oncol; 2016; 5(2):77-90. PubMed ID: 26986934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent synergy of dual antitumor peptides for growth suppression of human glioblastoma cell lines.
    Kondo E; Tanaka T; Miyake T; Ichikawa T; Hirai M; Adachi M; Yoshikawa K; Ichimura K; Ohara N; Moriwaki A; Date I; Ueda R; Yoshino T
    Mol Cancer Ther; 2008 Jun; 7(6):1461-71. PubMed ID: 18566217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1.
    Lee JS; Xiao J; Patel P; Schade J; Wang J; Deneen B; Erdreich-Epstein A; Song HR
    Neuro Oncol; 2014 Jan; 16(2):191-203. PubMed ID: 24305710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme.
    Solomon DA; Kim JS; Jean W; Waldman T
    Cancer Res; 2008 Nov; 68(21):8657-60. PubMed ID: 18974105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.
    Kato S; Schwaederle M; Daniels GA; Piccioni D; Kesari S; Bazhenova L; Shimabukuro K; Parker BA; Fanta P; Kurzrock R
    Cell Cycle; 2015; 14(8):1252-9. PubMed ID: 25695927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474).
    Lin L; Gaut D; Hu K; Yan H; Yin D; Koeffler HP
    Int J Oncol; 2014 Feb; 44(2):557-62. PubMed ID: 24297065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
    Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
    Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCL6 promotes glioma and serves as a therapeutic target.
    Xu L; Chen Y; Dutra-Clarke M; Mayakonda A; Hazawa M; Savinoff SE; Doan N; Said JW; Yong WH; Watkins A; Yang H; Ding LW; Jiang YY; Tyner JW; Ching J; Kovalik JP; Madan V; Chan SL; Müschen M; Breunig JJ; Lin DC; Koeffler HP
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3981-3986. PubMed ID: 28356518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
    Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
    PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.